Improving the rate of uptake of innovation is a win-win situation for industry, government, health systems and, most importantly, patients, and several examples exist across the EU and US with the UK’s Accelerated Access Review, the EU’s PRIME and breakthrough designation in the US.
The panel will discuss whether accelerated access systems could be used to test both new technologies and new business models, how they can help to establish specific countries as a destination for pharma/life sciences innovation and, within the UK, what else can industry do to help the government enable the UK to become a world leader in innovation use to deliver significantly better outcomes for NHS patients at an affordable cost.
The panel will also consider the implications of suppliers to the pharmaceutical industry managing more uncertainty over launch dates and product volumes, cross-border deal making and multinational clinical studies.
Jo Pisani Partner Pharmaceuticals & Lifesciences, Strategy& PricewaterhouseCoopers
James Xue Chairman and Chief Executive Officer, CANbridge Life Sciences
Mike Capaldi Chief Executive Officer, Sunergos Innovations
Mohit Misra Chief Medical Officer & Vice President Health Systems, Aetion
Amanda Begley Director of Innovation and Implementation, UCLPartners
Gino Martini Innovation & Outreach Lead, Roche Pharmaceuticals